Drugs / FRαDCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06639074 | Nov 2024 → Dec 2027 expected | fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma +6 | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRαDCs | “FRαDCs, a dendritic cell vaccine” NCT06639074 ↗ |
| Modality | Vaccine | “FRαDCs, a dendritic cell vaccine” NCT06639074 ↗ |